

**HEDIS<sup>®1</sup> for Measurement Year 2022**  
**Healthcare Effectiveness Data and Information Set**

\*Measures collected with medical record review    **Red= new/addition to measures**    **Blue= Medicare only**

New Measures	
Measure	Screening, test, or care needed
<p><b>Deprescribing of Benzodiazepines in Older Adults (DBO) *Medicare</b></p> <p><b>Adults 67 years of age and older</b></p> <p><b>Note: First year measure</b></p>	<ul style="list-style-type: none"> <li>• <b>Prescribed benzodiazepines who experienced a decrease 20% or more in the average daily benzodiazepine dose during the measurement year.</b></li> </ul> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>• <b>Members with a diagnosis of seizure disorder, REM Sleep Behavior disorder, Benzodiazepine withdrawal, or Ethanol Withdrawal on or before January 1 of the year prior to the measurement year and the ITE start date.</b></li> <li>• <b>Members in Hospice or using Hospice services or receiving Palliative Care during the measurement year are also excluded.</b></li> </ul>
<p><b>Antibiotic Utilization for Respiratory Conditions (AXR)</b></p> <p><b>Ages 3 months and older</b></p> <p><b>Note: First year measure</b></p>	<ul style="list-style-type: none"> <li>• <b>Members 3 months of age and older with a diagnosis of a respiratory condition that resulted in an antibiotic dispensing event.</b></li> </ul> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>• <b>Members in Hospice or using Hospice services during the measurement year are also excluded.</b></li> </ul>
<p><b>Advance Care Planning (ACP) *Medicare</b></p> <p><b>Adults 66 -80 years of age diagnosed with advanced illness (an indication of frailty) or receiving Palliative care.</b></p> <p><b>Note: First year Measure</b></p>	<ul style="list-style-type: none"> <li>• <b>Advanced Care Planning is the discussion or documentation about preferences for resuscitation, life-sustaining treatment, and end of life care.</b></li> </ul> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>• <b>Members in hospice or using hospice services anytime during the measurement year.</b></li> </ul>

<sup>1</sup> HEDIS<sup>®</sup> is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS<sup>®</sup> MY 2022, please contact the Quality Improvement Dept. at 757-252-8400 or toll-free at 1-844-620-1015

Prevention and Screening	
Measure	Screening, test, or care needed
<p><b>*Childhood Immunization</b></p> <p>Children who turn 2 years old during the measurement year (2021).</p> <p>Vaccines must be completed <u>on or before the 2<sup>nd</sup> birthday</u></p>	<ul style="list-style-type: none"> <li>• 4 DTaP, <b>anaphylaxis, or encephalitis due to diphtheria, tetanus or pertussis vaccine</b> (do not count any before 42 days of age)</li> <li>• 3 IPV (do not count any before 42 days of age)</li> <li>• 1 MMR <b>or history of measles, mumps, and rubella</b> (do not count any before 42 days of age)</li> <li>• 3 HiB <b>or anaphylaxis to HiB vaccine</b> (do not count any before 42 days of age)</li> <li>• 3 Hepatitis B, <b>anaphylaxis due to hepatitis B vaccine, positive serology, or history of hepatitis B</b></li> <li>• 1 VZV, <b>positive serology, or documented history of chicken pox disease</b></li> <li>• 4 pneumococcal conjugates (do not count any before 42 days of age)</li> <li>• 1 Hepatitis A, <b>or documented Hepatitis A illness</b></li> <li>• 2 or 3 Rotavirus vaccines-depends on the vaccine administered (do not count any before 42 days of age), <b>or documented anaphylaxis due to the rotavirus vaccine</b></li> <li>• 2 Influenza with different dates of service. One of the two vaccinations can be an LAIV- live attenuated influenza vaccine- if administered on the child’s 2nd birthday. (do not count any given prior to 6 months of age)</li> </ul> <p><b>Exclusions: Members in hospice or using hospice services any time during the Measurement Period</b> <u>or</u> <b>Any of the following on or before the child’s second birthday:</b></p> <ul style="list-style-type: none"> <li>- <b>Severe combined immunodeficiency.</b></li> <li>- <b>Immunodeficiency.</b></li> <li>- <b>HIV</b></li> <li>- <b>Lymphoreticular cancer, multiple myeloma, or leukemia.</b></li> <li>- <b>Intussusception</b></li> </ul> <p>Documentation of “immunizations are up-to-date” is <u>not</u> acceptable.</p> <p>Documentation of an immunization (such as the first Hep B) received “at delivery “or “in the hospital” may be counted.</p> <p><b>Documented history of illness, a seropositive test result or anaphylaxis, there must be a note indicating the date of the event, which must have occurred by the member’s second birthday.</b></p> <p>Parental refusal is <u>not</u> an exclusion</p>

<sup>1</sup> HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

Prevention and Screening

Measure	Screening, test, or care needed
<p><b>*Immunizations for Adolescents</b></p> <p>NOTE: This measure includes the Human Papillomavirus Vaccine (HPV) for <u>both males and females</u>.</p> <p>All vaccines must be completed on or before the 13<sup>th</sup> birthday.</p> <p>Children who turn 13 years old during the measurement year (2021).</p> <p><b>CPT Codes:</b> Meningococcal: 90734 Tdap: 90715 HPV: 90649-90651</p>	<ul style="list-style-type: none"> <li>• 1 dose <b>Meningococcal</b> vaccine between the 11<sup>th</sup> and 13<sup>th</sup> birthdays or anaphylaxis due to the vaccine anytime on or before the 13<sup>th</sup> birthday <b>and</b></li> <li>• 1 tetanus, diphtheria toxoids and acellular pertussis (<b>Tdap</b>) vaccine between the 10<sup>th</sup> and 13<sup>th</sup> birthdays or anaphylaxis due to the vaccine anytime on or before the 13<sup>th</sup> birthday <b>and</b></li> <li>• 2-dose <u>or</u> 3-dose <b>HPV</b> vaccination series between the 9<sup>th</sup> and 13<sup>th</sup> birthdays or anaphylaxis due to the vaccine anytime on or before the 13<sup>th</sup> birthday</li> </ul> <p><b>Documentation of “immunizations are up-to-date” is <u>not</u> acceptable.</b></p> <p><b>For documented history of anaphylaxis, there must be a note indicating the date of the event, which must have occurred by the member’s 13th birthday.</b></p> <p><b>Exclusions: Members in hospice or using hospice services any time during the Measurement Period</b></p> <p><b>Parental refusal is <u>not</u> an exclusion</b></p>
<p><b>*Lead Screening in Children (Medicaid only)</b></p> <p>Children who turn 2 years old during the measurement year (2021).</p> <p><b>CPT Code:</b> 83655</p>	<p>At least one capillary or venous lead blood test <b>by their 2<sup>nd</sup> birthday</b>.</p> <p><b>Documentation in the record must include <u>both</u> of the following:</b></p> <ul style="list-style-type: none"> <li>• <b>Date the test was performed</b></li> <li>• <b>The result or finding</b></li> </ul> <p><b>Exclusions: Members in hospice or using hospice services any time during the Measurement Period</b></p>

<sup>1</sup> HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

## Prevention and Screening

Measure	Screen, Test, Care needed
<p><b>*Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents</b></p> <p>Members 3-17 years of age, who had an outpatient visit with a PCP or OB/GYN during 2021 and had evidence of the following documented:</p> <ul style="list-style-type: none"> <li>BMI percentile</li> <li>Counseling for Nutrition</li> <li>Counseling for Physical Activity</li> </ul> <p><b>ICD-9 Codes:</b> BMI percentile: Z68.51-Z68.54 Counseling for nutrition: Z71.3 Counseling for physical activity: Z02.5; Z71.82</p> <p><b>CPT Codes</b> Counseling for nutrition: 97802-97804</p>	<p>BMI Percentile documentation must include <b>date, height, weight</b> and:</p> <ul style="list-style-type: none"> <li><b>BMI percentile</b> (may be plotted on age-growth chart)</li> <li><b>Weight and height must be taken during the measurement year (2021).</b></li> </ul> <p>Counseling for Nutrition documentation must include a note indicating the <b>date</b> and <b>at least one of the following:</b></p> <ul style="list-style-type: none"> <li>Discussion of current nutrition behaviors (e.g., eating habits, dieting behaviors)</li> <li>Checklist indicating nutrition was addressed</li> <li>Counseling or referral for nutrition education</li> <li>Member received educational materials on nutrition during a face-to-face visit</li> <li>Anticipatory guidance for nutrition</li> <li>Weight or obesity counseling</li> <li>Referral to WIC</li> </ul> <p>Counseling for Physical Activity documentation includes a note indicating the <b>date</b> and <b>at least one of the following:</b></p> <ul style="list-style-type: none"> <li>Discussion of current physical activity behaviors (e.g., exercise routine, participation in sports activities, exam for sports participation)</li> <li>Checklist indicating physical activity was addressed</li> <li>Counseling or referral for physical activity</li> <li>Member received educational materials on physical activity during a face-to-face visit</li> <li>Anticipatory guidance specific to the child's physical activity</li> <li>Weight or obesity counseling</li> </ul> <p><b>Documentation of meeting Developmental Milestones only does <u>not</u> meet HEDIS® criteria for Physical Activity Counseling.</b></p> <p><b>Services specific to an acute or chronic condition do <u>not</u> count toward the counseling indicators for either nutrition or physical activity.</b></p> <p><b>Exclusions:</b> <b>Members in hospice or using hospice services anytime during the measurement year.</b></p>

<sup>1</sup> HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

Prevention and Screening	
Measure	Screen, Test, Care needed
<p><b>*Cervical Cancer Screening</b> Women ages 21-64</p> <p><b><u>CPT Codes to identify Cervical Cancer Screening</u></b></p> <p>Cervical cytology: 88141-88143; 88147-88148; 88150. 88152-88154; 88164- 88167; 88174-88175</p> <p>HPV tests: 87620-87622; 87624-87625</p> <p><b>Note:</b> Evidence of hrHPV testing within the last 5 years also captures patients who had cotesting; therefore, additional methods to identify cotesting are not necessary.</p>	<ul style="list-style-type: none"> <li>• <b>A PAP test (cervical cytology)</b> within the last 3 years (2019-2021) for women <b>ages 21-64</b></li> <li>• <b>Cervical high-risk human papillomavirus (hrHPV) testing</b> within the last 5 years (2017-2021) for women <b>ages 30-64.</b></li> <li>• <b>Cervical cytology/high-risk human papillomavirus (hrHPV) co-testing</b> within the last 5 years (2017-2021) for women <b>ages 30-64.</b></li> </ul> <p><b><u>Exclusion:</u></b></p> <ul style="list-style-type: none"> <li>• <b>Members in hospice or using hospice services anytime during the measurement year.</b></li> <li>• <b>Members receiving palliative care during the measurement year.</b></li> <li>• <b>Documentation of hysterectomy with <u>no residual cervix is required:</u></b> <ul style="list-style-type: none"> <li>– “Complete”, “total” or “radical hysterectomy (abdominal, vaginal or unspecified)”</li> <li>– “Vaginal hysterectomy”</li> <li>– “Vaginal pap smear” in conjunction with “hysterectomy”</li> <li>– “Hysterectomy” in combination with documentation that member no longer needs pap test/cervical cancer screening</li> </ul> </li> </ul> <p>Documentation of “hysterectomy” <b><u>alone</u></b> does <b><u>not</u></b> meet the criteria.</p>
<p><b>Non-Recommended Cervical Cancer Screening in Adolescent Females</b></p> <p>Adolescent females ages 16-20</p>	<ul style="list-style-type: none"> <li>• screened unnecessarily for cervical cancer.</li> </ul> <p><b><u>Note:</u></b> A lower rate indicates better performance</p> <p><b><u>Exclusion:</u></b></p> <ul style="list-style-type: none"> <li>• History of cervical cancer, HIV, or immunodeficiency</li> <li>• <b>Members in hospice or using hospice services anytime during the measurement year</b></li> </ul>

<sup>1</sup> HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS® MY 2022, please contact the Quality Improvement Dept. at 757-252-8400 or toll-free at 1-844-620-1015

Prevention and Screening	
Measure	Screen, Test, Care needed
<p><b>Chlamydia Screening</b></p> <p>Females ages 16-24 and identified as sexually active (by claims or pharmacy data)</p> <p>CPT Codes for Chlamydia Screening: 87110; 87270; 87320; 87490- 87492; 87810</p>	<ul style="list-style-type: none"> <li>At least one test for Chlamydia during the measurement year (2021).</li> </ul> <p><b>Exclusion:</b></p> <p>A pregnancy test <i>alone</i> during the measurement year <b>and either:</b></p> <ul style="list-style-type: none"> <li>A prescription for isotretinoin on the date of the pregnancy test or six days after the pregnancy test.</li> <li>An x-ray on the date of pregnancy test or the six days after the pregnancy test</li> <li><b>Members in hospice or using hospice services anytime during the measurement year.</b></li> </ul>
<p><b>Breast Cancer Screening</b></p> <p>Women ages 50-74</p> <p>CPT Codes to identify Mammography: 77055-77057; 77061-77063; 77065-77067</p>	<ul style="list-style-type: none"> <li>A mammogram (screening, diagnostic, digital or digital breast tomosynthesis) <b>on or between October 1, 2019 -December 31, 2021.</b></li> </ul> <p><b>NOTE:</b> MRI's, ultrasounds or biopsies <i>alone</i> do not count- a mammogram is also required.</p> <p><b>Exclusion:</b></p> <ul style="list-style-type: none"> <li><b>Bilateral Mastectomy</b></li> <li><b>Members in hospice or using hospice services anytime during the measurement year</b></li> <li><b>Members receiving palliative care during the measurement year</b></li> </ul>
<p><b>Non-recommended PSA-Based Screening in Older Men</b></p> <p>Men age 70 and older</p> <p><u>CPT codes for PSA-based Screening:</u> 84152-84154</p>	<ul style="list-style-type: none"> <li>Screened unnecessarily for prostate cancer</li> </ul> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>Prostate cancer diagnosis</li> <li>Dysplasia of the prostate</li> <li>A PSA test during the year <i>prior to</i> the measurement year (2020) where laboratory data indicate an elevated result or abnormal finding.</li> <li>Dispensed prescription for a 5-alpha reductase inhibitor during the measurement year (2021).</li> <li>Members in hospice or using hospice services anytime during the measurement year.</li> </ul>

<sup>1</sup> HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS® MY 2022, please contact the Quality Improvement Dept. at 757-252-8400 or toll-free at 1-844-620-1015

Prevention and Screening	
Measure	Screen, Test, Care Needed
<p><b>*Colorectal Cancer Screening</b></p> <p>Adults ages 50-75</p> <p><b><u>CPT Codes for Colorectal Cancer Screening:</u></b></p> <p><i>FOBT:</i> 82270; 82274</p> <p><i>FIT-DNA:</i> 81528</p> <p><i>Flexible Sigmoidoscopy:</i> 45330-45335; 45337-45342; 45345-45347; 45349-45350</p> <p><i>CT Colonography:</i> 74261-74263</p> <p><i>Colonoscopy:</i> 44388-44394; 44397; 44401-44408; 45355; 45378-45393; 45398</p>	<p><b>One</b> or more of the following screenings:</p> <ul style="list-style-type: none"> <li>• Colonoscopy <b>in past 10 years (2012-2021)</b></li> <li>• Flexible sigmoidoscopy <b>in past 5 years (2017-2021)</b></li> <li>• CT Colonography (e.g., virtual colonoscopy) <b>in the past 5 years (2017-2021)</b></li> <li>• FIT-DNA (e.g., Cologuard) test <b>in the past 3 years (2019-2021)</b></li> <li>• Fecal occult blood test (iFOBT or gFOBT) <b>annually (2021)</b></li> </ul> <p><b>Exclusion:</b></p> <ul style="list-style-type: none"> <li>• <b>Diagnosis of colorectal cancer or total colectomy.</b></li> <li>• <b>Members in hospice or using hospice services anytime during the measurement year.</b></li> </ul>
Utilization and Risk Adjusted Utilization	
Measure	Screening, test or care needed
<p><b>Well-child Exams in the First 30 Months of Life</b></p> <p>Children who turned 15 months or 30 months during 2021</p> <p><b><u>CPT Codes to Identify Well-Child Visits:</u></b> 99381-99385; 99391-99395; 99461</p> <p><b><u>ICD-10 Codes:</u></b> Z00.00-Z00.01; Z00.110-Z00.111; Z00.121; Z00.129; Z00.2; Z00.3; Z00.5; Z76.1-Z76.2</p>	<p><b>Well-care visits</b> with a PCP/Pediatrician.</p> <p>Two rates are reported:</p> <ul style="list-style-type: none"> <li>• <b>Six</b> (6) or more well visits on different dates of service <b>on or before the 15-month birthday</b></li> <li>• <b>Two</b> (2) or more well visits on different dates of service <b>between the child's 15-month birthday plus one day and the 30-month birthday</b></li> </ul> <p><b>Exclusion:</b></p> <ul style="list-style-type: none"> <li>• <b>Members in hospice or using hospice services anytime during the measurement year.</b></li> </ul>

<sup>1</sup> HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS® MY 2022, please contact the Quality Improvement Dept. at 757-252-8400 or toll-free at 1-844-620-1015

## Utilization and Risk Adjusted Utilization

Measure	Screening, test or care needed
<p><b>Child and Adolescent Well-Care Visits</b></p> <p>Ages 3-21 years</p> <p><b>CPT Codes to Identify Well-Child Visits</b> 99381-99385; 99391-99395; 99461</p> <p><b>ICD-10 Codes:</b> Z00.00-Z00.01; Z00.110-Z00.111; Z00.121; Z00.129; Z00.2; Z00.3; Z00.5; Z76.1-Z76.2</p>	<ul style="list-style-type: none"> <li>At least <b>one</b> (1) comprehensive well-care visit with a PCP or OB/GYN practitioner during the measurement year (2021).</li> </ul> <p><b>Exclusion:</b></p> <ul style="list-style-type: none"> <li>Members in hospice or using hospice services anytime during the measurement year.</li> </ul>

## Respiratory Conditions

Measure	Screening, Test, Care Needed
<p><b>Appropriate Testing for Pharyngitis</b></p> <p>Ages 3 years and older</p> <p><b>ICD-10 Codes to Identify Pharyngitis:</b> J02.0; J02.8-J02.9; J03.00-J03.01; J03.80-J03.81; 03.90-J03.91</p>	<ul style="list-style-type: none"> <li>Diagnosis of pharyngitis</li> <li>Prescribed an antibiotic</li> </ul> <p><b>and</b></p> <p>Received a group A streptococcus (strep) test in the 7-day period from 3 days <i>prior to</i>, through 3 days <i>after</i>, the prescription date.</p> <p><b>Exclusion:</b></p> <ul style="list-style-type: none"> <li>Members in hospice or using hospice services anytime during the measurement year.</li> </ul>
<p><b>Appropriate Treatment for Upper Respiratory Infection</b></p> <p>Ages 3 months and older</p> <p><b>ICD-10 Codes to identify URI:</b> J00; J06.0; J06.9</p>	<ul style="list-style-type: none"> <li>Diagnosis of Upper Respiratory Infection (URI), <b>and Not</b> prescribed an antibiotic.</li> </ul> <p><b>Exclusion:</b></p> <ul style="list-style-type: none"> <li>Members in hospice or using hospice services anytime during the measurement year.</li> </ul>

<sup>1</sup> HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS® MY 2022, please contact the Quality Improvement Dept. at 757-252-8400 or toll-free at 1-844-620-1015

## Respiratory Conditions

Measure	Screening, Test, Care Needed
<p><b>Avoidance of Antibiotic Treatment for Bronchitis/Bronchiolitis</b></p> <p>Ages 3 months and older</p> <p><u>ICD-10 Codes to identify Acute Bronchitis:</u> J20.3-J20.9; J21.0-J21.1; J21.8-J21.9</p>	<ul style="list-style-type: none"> <li>• Diagnosis of acute bronchitis/bronchiolitis, and Not dispensed an antibiotic prescription</li> </ul> <p><b>Exclusion:</b></p> <ul style="list-style-type: none"> <li>• <b>Members in hospice or using hospice services anytime during the measurement year.</b></li> <li>• <b>Members with a diagnosis of any of the following comorbid conditions: Emphysema; COPD; Immune system disorder; HIV; Malignant neoplasm</b></li> </ul>
<p><b>Use of Spirometry Testing in the Assessment and Diagnosis of COPD</b></p> <p>Adults ages 40 and older</p> <p><u>CPT Codes for Spirometry Testing:</u> 94010; 94014-94016; 94060; 94070; 94375; 94620</p>	<ul style="list-style-type: none"> <li>• Diagnosis of new, or newly active, COPD between July 1, 2020-June 30, 2021 <u>and</u></li> <li>• Spirometry testing to confirm the diagnosis in the 2 years prior through 6 months after the diagnosis.</li> </ul> <p><b>Exclusion:</b></p> <ul style="list-style-type: none"> <li>• <b>Members in hospice or using hospice services anytime during the measurement year.</b></li> </ul>
<p><b>Pharmacotherapy Management of COPD Exacerbation</b></p> <p>Adults ages 40 and older</p> <p><u>ICD-10 Codes to identify COPD:</u> J44.0; J44.1; J44.9</p>	<p>Discharged from an acute inpatient admission or an ED visit with a primary diagnosis of COPD on or between January 1 – November 30, 2021</p> <p><u>and</u></p> <ol style="list-style-type: none"> <li>1. Dispensed appropriate medications (or already had an active prescription for) both:</li> <li>2. A systemic corticosteroid within 14 days of the event</li> <li>3. A bronchodilator within 30 days of the event</li> </ol> <p><b>Exclusion:</b></p> <ul style="list-style-type: none"> <li>• <b>Members in hospice or using hospice services anytime during the measurement year.</b></li> </ul>

<sup>1</sup> HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

Cardiovascular	
Measure	Screening, test, care needed
<p><b>*Controlling High Blood Pressure</b></p> <p>Adults ages 18-85</p> <p><i>Adequate control</i> is defined as: &lt;140/90</p> <p><b>ICD-10 Codes to identify HTN:</b> I10</p> <p><b>CPT II Codes for BP values:</b></p> <p>Systolic Less than 140: 3074F, 3075F</p> <p>Systolic Greater than/Equal to 140: 3077F Diastolic Less than 80: 3078F</p> <p>Diastolic 80-89: 3079F</p> <p>Diastolic Greater than/Equal to 90: 3080F</p>	<ul style="list-style-type: none"> <li>• Diagnosis of hypertension</li> <li>• <b>Most recent blood pressure reading in the medical record for 2021.</b></li> </ul> <p><b>Exclusions:</b> Evidence of any of the following during 2021:</p> <ul style="list-style-type: none"> <li>– End Stage Renal Disease (ESRD), or dialysis</li> <li>– Kidney transplant</li> <li>– Pregnancy</li> <li>– Nonacute inpatient admission</li> <li>– Members in hospice or using hospice services anytime during the measurement year.</li> <li>– Members receiving palliative care during the measurement year.</li> </ul>
<p><b>Statin Therapy for Patients with Cardiovascular Disease</b></p> <p>Males ages 21-75; Females ages 40-75</p> <p><b>Moderate or high-intensity statin therapy:</b></p> <p>Atorvastatin: 10-80mg</p> <p>Amlodipine-atorvastatin: 10-80mg</p> <p>Rosuvastatin: 5-40mg</p> <p>Simvastatin: 20-80mg</p> <p>Ezetimibe-simvastatin: 20-80mg</p> <p>Pravastatin: 40-80mg</p> <p>Lovastatin: 40mg</p> <p>Fluvastatin 40-80mg</p> <p>Pitavastatin 2-4mg</p> <p><b>ICD-10 codes for myalgia/myositis/myopathy:</b></p> <p>G72.0; G72.2; G72.9; M60.80-M60.812; M60.819; M60.821-M60.822; M60.829; M60.831-M60.832; M60.839; M60.841-M60.842; M60.849; M60.851-M60.852; M60.859; M60.861-M60.862; M60.869; M60.871-M60.872; M60.879; M60.88-M60.89; M60.9; M62.82; M79.1-M79.12; M79.18</p>	<p>Identified as having clinical atherosclerotic cardiovascular disease (ASCVD) Two rates are reported:</p> <ol style="list-style-type: none"> <li><b>1. Received Statin Therapy:</b> Members who were dispensed at least one <i>high or moderate-intensity</i> statin medication during the measurement year (2021).</li> <li><b>2. Statin Adherence 80%:</b> Members who remained on a high or moderate-intensity statin medication for at least 80% of the treatment period (from prescription date through end of year).</li> </ol> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>– Pregnancy/IVF</li> <li>– ESRD or dialysis</li> <li>– Cirrhosis</li> <li>– Myalgia, myositis, myopathy, or rhabdomyolysis</li> <li>– Dispensed a Dementia medication</li> <li>– Members in hospice or using hospice services anytime during the measurement year.</li> <li>– Members receiving palliative care during the measurement year.</li> </ul>

<sup>1</sup> HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

## Cardiovascular

Measure	Screening, test, care needed
<p><b>Cardiac Rehabilitation 18 years and older</b></p> <p><b>CPT codes: 93797-93798</b></p>	<ul style="list-style-type: none"> <li>Attended cardiac rehabilitation following a qualifying cardiac event (myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, heart and heart/lung transplantation or heart valve repair/replacement).</li> </ul> <p>Four rates are reported:</p> <ul style="list-style-type: none"> <li><b>Initiation:</b> percentage of members who attended <b>2 or more sessions</b> of cardiac rehabilitation <b>within 30 days</b> after a qualifying event.</li> <li><b>Engagement 1:</b> percentage of members who attended <b>12 or more sessions</b> of cardiac rehabilitation <b>within 90 days</b> after a qualifying event.</li> <li><b>Engagement 2:</b> percentage of members who attended <b>24 or more sessions</b> of cardiac rehabilitation <b>within 180 days</b> after a qualifying event</li> </ul> <p><b>Achievement:</b> percentage of members who attended <b>36 or more sessions</b> of cardiac rehabilitation <b>within 180 days</b> after a qualifying event.</p> <p><b>Exclusion:</b> Members in hospice or using hospice services anytime during the measurement year.</p>

Diabetes	
<p><b>*Comprehensive Diabetes Care has been revised into three standalone Measures</b></p> <p>Adults ages 18-75 with diagnosis of diabetes (type 1 or type 2) or who have been prescribed insulin or hypoglycemic/antihyperglycemics.</p> <p><b>ICD-10 Codes to identify Diabetes:</b> E10.10-E10.9; E11.00-E11.9; E13.00-E13.9</p> <p><b>CPT II codes for Diabetic retinal Screening:</b> 3072F; 2022F; 2023F; 2024F; 2025F; 2026F; 2033F</p> <p><b>CPT II Codes for BP values:</b> Systolic Less than 140: 3074F, 3075F Systolic Greater than/Equal to 140: 3077F Diastolic Less than 80: 3078F Diastolic 80-89: 3079F Diastolic Greater than/Equal to 90: 3080F</p>	<ol style="list-style-type: none"> <li><b>Blood Pressure Control for Patients with Diabetes (BPD)</b> examines members 18-75 years of age with diabetes (types 1 and 2) whose blood pressure (BP) was controlled (&lt;140/90 mm Hg) during the measurement year. <b>(most recent date and result from 2021)</b></li> <li><b>Hemoglobin A1c Control for Patients with Diabetes (HBD)</b> examines members 18-75 years of age with Diabetes (type 1 and 2) whose Hb A1c was at the following levels during the measurement year. <b>(Most recent result from 2021)</b> <ul style="list-style-type: none"> <li>HbA1c control (&lt;8.0%)</li> <li>HbA1c poor control (&gt;9.0%)</li> </ul> </li> <li><b>Eye Exam for Patients with Diabetes (EED)</b> examines members 18-75 years of age with diabetes (types 1 and 2) who had a retinal eye exam. <b>(Most recent date and result from 2020 or 2021 or bilateral eye enucleation anytime through 2021).</b></li> </ol> <p><b>Exclusions:</b> Members without a diagnosis of diabetes in any setting, but did have:</p> <ul style="list-style-type: none"> <li>Gestational Diabetes</li> <li>Steroid Induced Diabetes or</li> <li>Polycystic ovarian syndrome (during 2020 or 2021)</li> <li>Members in Hospice or using Hospice services during the measurement year.</li> <li>Members receiving palliative care during the measurement year.</li> </ul>

<sup>1</sup> HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

Diabetes	
Measure	Screening test or care needed
<p>Kidney Health Evaluation for Patients with Diabetes</p> <p>Adults ages 18-85</p> <p><b>CPT codes:</b> eGFR: 80047-80048; 80050; 80053; 80069; 82565 uACR: 82043; 82570</p>	<ul style="list-style-type: none"> <li>• Diagnosis of diabetes (type 1 and type 2)</li> <li>• Received a kidney health evaluation, defined by: <ul style="list-style-type: none"> <li>• an estimated glomerular filtration rate (eGFR)</li> <li><b>and</b></li> <li>• A urine albumin-creatinine ratio (uACR)</li> </ul> </li> </ul> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>• <b>Members in hospice or using hospice services anytime during the measurement year</b></li> <li>• <b>Members receiving palliative care during the measurement year.</b></li> <li>• ESRD</li> <li>• Dialysis</li> </ul>
<p>Statin Therapy for Patients with Diabetes</p> <p>Adults ages 40-75</p> <p><b>ICD-10 codes for myalgia, myositis, myopathy:</b> G72.0; G72.2; G72.9; M60.80-M60.812; M60.819; M60.821-M60.822; M60.829; M60.831-M60.832; M60.839; M60.841-M60.842; M60.849; M60.851- M60.852; M60.859; M60.861-M60.862; M60.869; M60.871-M60.872; M60.879; M60.88-60.89; M60.9; M62.82; M79.1-M79.12; M79.18</p>	<ul style="list-style-type: none"> <li>• <b>Identified as having diabetes and do not have ASCVD (clinical atherosclerotic cardiovascular disease) who met the following criteria:</b></li> </ul> <p><b>Two rates are reported:</b></p> <ol style="list-style-type: none"> <li>1. <b>Received Statin Therapy: Members who were dispensed at least one statin medication of any intensity during the measurement year (2021).</b></li> <li>2. <b>Statin Adherence 80%: Members who remained on a statin medication of any intensity for at least 80% of the treatment period (from prescription date through end of year).</b></li> </ol> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>• <b>Myalgia, myositis, myopathy, or rhabdomyolysis (in 2021)</b></li> <li>• <b>Any of the following (in 2020 or 2021): Polycystic ovarian syndrome; Pregnancy/IVF; Prescribed clomiphene; ESRD or dialysis; Cirrhosis</b></li> <li>• <b>Members in hospice or using hospice services anytime during the measurement year</b></li> <li>• <b>Members receiving palliative care during the measurement year.</b></li> </ul>

<sup>1</sup> HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS® MY 2022, please contact the Quality Improvement Dept. at 757-252-8400 or toll-free at 1-844-620-1015

Musculoskeletal																	
Measure	Screening test or care needed																
<p>Osteoporosis Screening in Older Women</p> <p>Women ages 65-75</p> <p><b>CPT codes:</b> 76977; 77078; 77080-77081; 77085</p>	<ul style="list-style-type: none"> <li>Received one or more osteoporosis screening tests between their 65<sup>th</sup> birthday and December 31<sup>st</sup> of the measurement year (2021).</li> </ul> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>History of osteoporosis medication therapy</li> <li>Filled prescription for medication to treat osteoporosis</li> <li>Members in hospice or using hospice services anytime during the measurement year</li> <li>Members receiving palliative care during the measurement year.</li> </ul>																
<p><b>Osteoporosis Management in Women who had a Fracture</b></p> <p>Women ages 67-85</p> <p><b>CPT Codes to identify BMD test:</b> 76977; 77078; 77080-77081; 77085-77086</p> <p><b>HCPCS codes for osteoporosis meds:</b> J0897; J1740; J3110; J3489</p>	<p>Suffered a fracture and had <b>one of the following</b> in the 6 months after the fracture:</p> <p>A bone mineral density (BMD) test <i>or</i> A prescription for a drug to treat osteoporosis</p> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>Members in hospice or using hospice services anytime during the measurement year</li> </ul>																
<p><b>Use of Imaging Studies for Low Back Pain (Revised)</b></p> <p>Adults ages 18- 75</p> <p><b>ICD-10 Codes to identify Uncomplicated Low Back Pain:</b> M47.26-M47.28; M47.816-M47.898; M48.06-M48.08; M51.16-M51.17; M51.26-M51.87; M53.2X6-M53.2X8-M53.88; M54.16-M54.9; M99.03-M99.84 S33.100A-S33.9XXA; S39.002A-S39.92XS</p>	<ul style="list-style-type: none"> <li>Primary diagnosis of low back pain who</li> <li><b>did not</b> have an imaging study (x-ray, MRI, CT) within 28 days of the diagnosis.</li> </ul> <p>– A <b>higher score</b> indicates <b>appropriate treatment</b> of low back pain</p> <p><b>Exclusions:</b> An imaging study in the presence of low back pain is considered <b>clinically indicated</b> in patients with a diagnosis of:</p> <table border="0" style="width: 100%;"> <tr> <td>Lumbar surgery</td> <td>Spondylopathy</td> <td>Fragility fracture</td> <td>Palliative care/Advanced illness frailty</td> </tr> <tr> <td>Osteoporosis</td> <td>Cancer</td> <td>Recent Trauma</td> <td></td> </tr> <tr> <td>IV Drug Use</td> <td>Neurologic Impairment</td> <td>Prolonged Use of Corticosteroids</td> <td></td> </tr> <tr> <td>Major Organ Transplant</td> <td>Spinal Infection</td> <td>HIV</td> <td></td> </tr> </table> <ul style="list-style-type: none"> <li>Members in hospice or using hospice services anytime during the measurement year</li> </ul>	Lumbar surgery	Spondylopathy	Fragility fracture	Palliative care/Advanced illness frailty	Osteoporosis	Cancer	Recent Trauma		IV Drug Use	Neurologic Impairment	Prolonged Use of Corticosteroids		Major Organ Transplant	Spinal Infection	HIV	
Lumbar surgery	Spondylopathy	Fragility fracture	Palliative care/Advanced illness frailty														
Osteoporosis	Cancer	Recent Trauma															
IV Drug Use	Neurologic Impairment	Prolonged Use of Corticosteroids															
Major Organ Transplant	Spinal Infection	HIV															

<sup>1</sup> HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS® MY 2022, please contact the Quality Improvement Dept. at 757-252-8400 or toll-free at 1-844-620-1015

Behavioral Health	
Measure	Screening test or care needed
<p><b>Follow-up Care for Children Prescribed ADHD Medication</b></p> <p>Ages 6-12 years</p>	<ul style="list-style-type: none"> <li>An initial prescription for ADHD medication (or first fill in &gt;120 days)</li> <li>Remained on the medication</li> <li>Had appropriate follow up care visits</li> </ul> <p>Two rates are reported:</p> <ol style="list-style-type: none"> <li><b>Initiation Phase:</b> <ul style="list-style-type: none"> <li>one follow-up visit with a prescribing practitioner within 30 days</li> </ul> </li> <li><b>Continuation and Maintenance Phase:</b> <ul style="list-style-type: none"> <li>remained on the medication for at least 210 days and</li> <li>had two additional visits with a practitioner within 270 days (9 months after the Initiation Phase ended).</li> </ul> </li> </ol> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>Members in hospice or using hospice services anytime during the measurement year.</li> <li>Members with a diagnosis of narcolepsy anytime during their history through the measurement year.</li> </ul>
<p><b>Metabolic Monitoring for Children and Adolescents on antipsychotics</b></p> <p>Children/Adolescents ages 1-17</p> <p><u>CPT Codes to identify cholesterol tests other than LDL:</u> 82465; 83718; 83722; 84478</p>	<ul style="list-style-type: none"> <li>At least 2 antipsychotic prescriptions (same or different medications) on different dates during the measurement year (2021)</li> <li>Blood glucose <u>or</u> HbA1c test during the measurement year (2021) <b>and</b> LDL-C <u>or</u> cholesterol test during the measurement year (2021)</li> </ul> <p><b>Exclusion:</b> Members in hospice or using hospice services anytime during the measurement year.</p>
<p><b>Antidepressant Medication Management</b></p> <p>Adults ages 18 and older</p> <p><u>ICD-10 Codes to identify Major Depression:</u> F32.0-F32.4; F32.9; F33.0- F33.3; F33.41; F33.9</p>	<ul style="list-style-type: none"> <li>Were treated with antidepressant medication</li> <li>Had a diagnosis of major depression <b>and</b></li> <li>Remained on antidepressant medication treatment.</li> </ul> <p>Two rates are reported:</p> <ol style="list-style-type: none"> <li>Effective <b>acute phase:</b> remained on an antidepressant medication for at least 84 days (<b>12weeks</b>)</li> <li>Effective <b>continuation phase:</b> remained on an antidepressant medication for at least 180 days (<b>6months</b>)</li> </ol> <p><b>Exclusion:</b> Members in hospice or using hospice services anytime during the measurement year.</p>

<sup>1</sup> HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

Behavioral Health	
Measure	Screen, Test, care needed
<p><b>Adherence to Antipsychotic Medications for Individuals with Schizophrenia</b> Ages 18 and older</p>	<ul style="list-style-type: none"> <li>• Diagnosis of Schizophrenia/schizoaffective disorder</li> <li>• Dispensed an antipsychotic medication <b>and</b> remained on the medication for at least 80% of their <i>treatment period</i> (days between the earliest prescription fill in 2021 and the end of the year)</li> </ul> <p><b>Exclusion:</b> Members in hospice or using hospice services anytime during the measurement year.</p>
<p><b>Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who are Using Antipsychotic Medications</b></p> <p>Adults ages 18-64</p> <p><b>ICD-10 Codes to identify diagnosis:</b> Bipolar: F30.10-F30.13; F30.2-F30.4; F30.8-F30.9; F31.0; F31.10-F31.13; F31.2; F31.30-F31.32; F31.4-F31.5; F31.60- F31.64; F31.70-F31.78; F31.81; F31.89; F31.9</p> <p>Schizophrenia: F20.0-F20.3; F20.5; F20.81; F20.89; F20.9; F25.0-F25.1; F25.8- F25.9</p>	<ul style="list-style-type: none"> <li>• Diagnosis of Schizophrenia, Schizoaffective Disorder or Bipolar Disorder</li> <li>• Dispensed an Antipsychotic medication on an ambulatory basis</li> <li>• Diabetes screening (glucose or HbA1c) test during the measurement year (2021)</li> </ul> <p><b>CPT Codes to Identify Diabetes Screening:</b> Glucose tests: 80047, 80048, 80050, 80053, 80069, 82947, 82950, 82951 HbA1c tests: 83036, 83037</p> <p><b>Exclusion:</b> Members in hospice or using hospice services anytime during the measurement year.</p>
<p><b>Diabetes Monitoring for People with Diabetes and Schizophrenia</b></p> <p>Adults ages 18-64</p>	<ul style="list-style-type: none"> <li>• Diagnosis of Schizophrenia/schizoaffective disorder <b>and</b> Diabetes</li> <li>• HbA1c test during the measurement year (2021) <b>and</b></li> <li>• LDL-C test (direct or calculated) during the measurement year (2021)</li> </ul> <p><b>Exclusion:</b> Members in hospice or using hospice services anytime during the measurement year.</p>
<p><b>Cardiovascular Monitoring for People with Cardiovascular Disease and Schizophrenia</b></p> <p>Adults ages 18-64</p>	<ul style="list-style-type: none"> <li>• Diagnosis of Schizophrenia/schizoaffective disorder <b>and</b> Cardiovascular Disease</li> <li>• LDL-C test (direct or calculated) during the measurement year (2021)</li> </ul> <p><b>CPT Codes to Identify LDL-C Screening:</b> 80061; 83700; 83701; 83704; 83721</p> <p><b>Exclusion:</b> Members in hospice or using hospice services anytime during the measurement year.</p>

<sup>1</sup> HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

Behavioral Health	
Measure	Screening, Test, Care Needed
<p><b>Follow-Up After Emergency Department Visit for Substance Use</b></p> <p>(Revised measure name from Follow Up After Emergency Department Visit for Alcohol and other Drug Abuse or Dependence)</p> <p><b>Ages 13 and older</b></p>	<p>ED visit with principal diagnosis of substance use disorder (SUD) or any diagnosis of drug overdose, for which there was a follow up.</p> <p>Two rates are reported:</p> <ol style="list-style-type: none"> <li>1. Follow-up visit <b>within 7 days of the ED visit (8 total days)</b></li> <li>2. Follow-up visit <b>within 30 days of the ED visit (31 total days)</b></li> </ol> <p><b>Exclusion:</b> Members in hospice or using hospice services anytime during the measurement year.</p>
<p><b>Follow-up After Hospitalization for mental Illness</b></p> <p>Ages 6 and over</p>	<ul style="list-style-type: none"> <li>• Hospitalized for treatment of selected mental illness or intentional self-harm <b>and</b></li> <li>• One follow-up outpatient visit, intensive outpatient encounter, or partial hospitalization <b>with a mental health provider.</b></li> </ul> <p>Two rates are reported:</p> <ol style="list-style-type: none"> <li>1. Follow-up visit within 7 days of discharge</li> <li>2. Follow-up visit within 30 days of discharge</li> </ol> <p><b>Exclusion:</b> Members in hospice or using hospice services anytime during the measurement year.</p>
<p><b>Follow-Up After High-Intensity Care for Substance Use Disorder</b></p> <p>Ages 13 and older</p>	<ul style="list-style-type: none"> <li>• Acute inpatient hospitalization, residential treatment, or detoxification visit</li> <li>• Diagnosis of substance use disorder</li> <li>• Follow-up visit or event with any practitioner for a <b>principal diagnosis of substance use disorder</b></li> </ul> <p>Two rates are reported:</p> <ol style="list-style-type: none"> <li>1. Follow-up within 7 days after the visit or discharge</li> <li>2. Follow-up within 30 days after the visit or discharge</li> </ol> <p><b>Exclusion:</b> Members in hospice or using hospice services anytime during the measurement year.</p>
<p><b>Pharmacotherapy for Opioid Use Disorder</b></p> <p>Ages 16 and older</p>	<ul style="list-style-type: none"> <li>• Diagnosis of opioid use disorder</li> <li>• Dispensed an opioid use disorder treatment medication (e.g., Naltrexone, Buprenorphine) Taken for 180 days</li> </ul> <p><b>Exclusion:</b> Members in hospice or using hospice services anytime during the measurement year.</p>

<sup>1</sup> HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS® MY 2022, please contact the Quality Improvement Dept. at 757-252-8400 or toll-free at 1-844-620-1015

Care Coordination	
Measure	Screen, Test, Care Needed
<p><b>Follow-Up After ED Visit for People with Multiple High-Risk Chronic Conditions</b></p> <p>Ages 18 and older</p>	<ul style="list-style-type: none"> <li>ED Visit</li> <li>Multiple (2 or more different) high-risk chronic conditions (e.g., COPD/asthma; dementia; CKD; major depression; heart failure; MI;atrial fibrillation; stroke)</li> </ul> <p>Follow-Up service within 7 days of the ED visit</p> <p><b>Exclusion:</b> Members in hospice or using hospice services anytime during the measurement year.</p>
<p><b>Transitions of Care</b></p> <p>Adults ages 18 and older</p> <p><u>CPT codes for Transitional Care Management Services and Medication Reconciliation:</u> 99483, 99495, 99496, 1111F</p>	<p><b>Documentation in the PCP record of the following in 2021:</b></p> <ul style="list-style-type: none"> <li><b>Notification of Inpatient Admission</b> on the day of admission through 2 days after</li> <li><b>Receipt of Discharge Information</b> on the day of discharge through 2 days after</li> <li><b>Patient Engagement After Inpatient Discharge</b> (e.g., office visits, home visits, telehealth) provided within 30 days after discharge.</li> <li><b>Medication Reconciliation conducted by a prescribing practitioner, clinical pharmacist or registered nurse</b> on the date of discharge through 30 days after discharge (documentation of review of <u>both</u> a list of the member’s current outpatient medications and the discharge medications, or notation that no medications were prescribed upon discharge).</li> </ul> <p><b>Exclusions:</b> Members in Hospice or using Hospice services during the measurement year are also excluded.</p>
Overuse/Appropriateness	
Measure	Screen, Test, care needed
<p><b>Risk of Continued Opioid Use</b></p> <p>Ages 18 and older</p>	<ul style="list-style-type: none"> <li>A new episode of opioid use that puts them at risk for continued opioid use</li> </ul> <p>Two rates are reported:</p> <ol style="list-style-type: none"> <li>The percentage of members with at least 15 days of prescription opioids in a 30-day period</li> <li>The percentage of members with at least 31 days of prescription opioids in a 62-day period</li> </ol> <p><u>NOTE:</u> A <i>lower</i> rate indicates better performance.</p> <p><b>Exclusion:</b> Members in hospice or using hospice services anytime during the measurement year.</p>

<sup>1</sup> HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

Overuse/Appropriateness	
Measure	Screen, Test, care needed
<p><b>Use of Opioids at High Dosage</b></p> <p>Ages 18 and older</p>	<ul style="list-style-type: none"> <li>Received prescription opioids at a high dosage (average morphine milligram equivalent dose [MME] <math>\geq 90</math>mg) for <math>\geq 15</math> days during measurement year (2021)</li> </ul> <p>NOTE: Reported as the rate per 1,000. A <i>lower</i> rate indicates better performance.</p> <p><b>Exclusion:</b> Members in hospice or using hospice services anytime during the measurement year.</p>
<p><b>Use of Opioids from Multiple Providers</b></p> <p>Ages 18 and older</p>	<p>Received prescription opioids for <math>\geq 15</math> days during 2021</p> <p>Three rates are reported: Above prescriptions received from and/or filled at:</p> <ul style="list-style-type: none"> <li>Multiple Prescribers (four or more different prescribers)</li> <li>Multiple Pharmacies (four or more different pharmacies)</li> <li>Multiple Prescribers and Multiple Pharmacies (<i>both</i> four or more prescribers <u>and</u> four or more pharmacies)</li> </ul> <p><b>Exclusion:</b> Members in hospice or using hospice services anytime during the measurement year.</p>
<p><b>Potentially Harmful Drug- Disease Interactions in Older Adults</b></p> <p>Ages 65 and older</p> <p>NOTE: A <i>lower</i> rate represents <i>better performance</i> for all rates.</p>	<ul style="list-style-type: none"> <li>Evidence of an underlying disease, condition, or health concern</li> <li>Dispensed an ambulatory prescription for a potentially harmful medication, concurrent with or after the diagnosis</li> </ul> <p>Three rates are reported:</p> <ol style="list-style-type: none"> <li>A <b>history of falls</b> and a prescription for antiepileptics, antipsychotics, benzodiazepines, non-benzodiazepine hypnotics, or antidepressants (SSRI's, tricyclic antidepressants, SNRI's)</li> <li><b>Dementia</b> and a prescription for antipsychotics, benzodiazepines, non-benzodiazepine hypnotics, tricyclic antidepressants, or anticholinergic agents.</li> <li><b>Chronic kidney disease</b> and a prescription for Cox-2 Selective NSAIDs or non-aspirin NSAIDs</li> </ol> <p><b>Exclusion:</b></p> <ul style="list-style-type: none"> <li>Members in hospice or using hospice services anytime during the measurement year.</li> <li>Members receiving palliative care during the measurement year.</li> <li>Members with a diagnosis of psychosis, schizophrenia, schizoaffective disorder, or bipolar disorder on or between January 1, 2020, to December 1, 2021.</li> </ul>

<sup>1</sup> HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

Overuse/Appropriateness	
Measure	Screen, test, care needed
<p><b>Use of High-Risk Medications in Older Adults</b></p> <p>Ages 67 and older</p> <p>NOTE: A <b>lower</b> rate represents <b>better performance</b>.</p>	<ul style="list-style-type: none"> <li>Received at least <b>two</b> dispensing events for high-risk medications to avoid from the same drug class (except for appropriate diagnoses).</li> </ul> <p><b>Exclusion:</b></p> <ul style="list-style-type: none"> <li>Members in hospice or using hospice services anytime during the measurement year.</li> <li>Members receiving palliative care during the measurement year.</li> </ul>
Access/Availability of Care	
Measure	Screen, tests, care needed
<p><b>Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics</b></p> <p>Ages 1-17 years</p> <p><b>Codes to identify psychosocial care: CPT:</b> 90832-90834; 90836-90840; 90845-90847; 90849; 90853; 90875-90876; 90880</p>	<ul style="list-style-type: none"> <li>A <b>new</b> prescription (4-month negative medication history) for an antipsychotic medication</li> <li>Documentation of psychosocial care as first-line treatment during the period from 90 days prior to 30 days after the prescription fill.</li> </ul> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>At least <b>one acute inpatient encounter, or at least 2 visits in an outpatient, intensive outpatient or partial hospitalization setting</b> with a diagnosis of <b>schizophrenia, schizoaffective disorder, bipolar disorder, other psychotic disorder, autism, or other developmental disorder</b> during the measurement year (2021)</li> <li>Members in hospice or using hospice services anytime during the measurement year.</li> </ul>
<p><b>Adult Access to Preventive/ Ambulatory Health Services</b></p> <p>Adults ages 20 and over</p>	<ul style="list-style-type: none"> <li>An ambulatory or preventive care visit <ul style="list-style-type: none"> <li>in the measurement year (2021) <b>for Medicaid and Medicare members</b></li> <li>in the measurement year or two years prior (2019-2021) <b>for Commercial members</b></li> </ul> </li> </ul> <p><b>Exclusion:</b> Members in hospice or using hospice services anytime during the measurement year.</p>

<sup>1</sup> HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS® MY 2022, please contact the Quality Improvement Dept. at 757-252-8400 or toll-free at 1-844-620-1015

Access/Availability of Care	
Measure	Screen, test, care needed
<p><b>*Prenatal/Postpartum Care</b></p> <p>Pregnant Women who delivered a live infant between <u>October 8, 2020 and October 7, 2021</u></p>	<ul style="list-style-type: none"> <li>• <b>Prenatal visit <u>within first trimester</u></b> (on or before the enrollment start date or within 42 days of enrollment)</li> <li>• <b>Postpartum visit on or <u>between 7 and 84 days</u> after delivery</b></li> </ul> <p><b>Exclusion:</b> Members in hospice or using hospice services anytime during the measurement year.</p>
<p><b>Initiation and Engagement of Substance Use Disorder Treatment</b></p> <p>Ages 13 and older</p> <p><b>Codes to identify AOD visits:</b> 98960- 98962; 99078; 99201-99205; 99211-99215; 99241-99245; 99341-99345; 99347-99350; 99384-99387; 99394-99397; 99401-99404; 99408-99409; 99411-99412; 99483; 99510</p>	<p>A new episode (194 days negative diagnosis history) of <b>substance use disorder (SUD)</b> that result in treatment initiation and engagement</p> <ul style="list-style-type: none"> <li>• <b>Initiation of SUD treatment <u>within 14 days</u></b> of the diagnosis through an inpatient SUD admission, outpatient visit, intensive outpatient encounter or partial hospitalization, telehealth, or medication treatment.</li> <li>• <b>Engagement of SUD treatment evidence of treatment engagement <u>within 34 days</u> of the initiation.</b></li> </ul> <p><b>Exclusion:</b> Members in hospice or using hospice services anytime during the measurement year.</p>
Measures Collected through CAHPS Survey (Consumer Assessment of Healthcare Providers and Systems)	
Measure	Screen, test care needed
<p><b>Medical Assistance with Smoking Cessation</b></p> <p>Current Smoker/Tobacco user ages 18 and older</p>	<ul style="list-style-type: none"> <li>• Received <b><u>advice to quit</u></b> during the measurement year (2021).</li> <li>• Discussed or were <b><u>recommended cessation medications</u></b> during the measurement year (2021).</li> </ul> <p>Discussed or were <b><u>provided cessation methods or strategies</u></b> during the measurement year (2021).</p>
<p><b>Flu Vaccinations for Adults</b> (ages 18-64) <b>Flu Vaccinations for Adults</b> (ages 65+)</p>	<p>Received an influenza vaccination <b>after July 1, 2021</b>.</p>
<p><b>Pneumococcal Vaccination Status for Older Adults</b></p> <p><b>Ages 65 and older</b></p>	<p>Have <b><u>ever received</u></b> one or more pneumococcal vaccinations</p>

<sup>1</sup> HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS® MY 2022, please contact the Quality Improvement Dept. at 757-252-8400 or toll-free at 1-844-620-1015

## Measures Collected through Medicare Health Outcomes Survey (HOS)

Measure	Screen, test, care needed
<p><b>Fall Risk Management</b></p> <p>Adults ages 65 and older</p>	<ol style="list-style-type: none"> <li>1. <i>Discussing</i> Fall Risk <ul style="list-style-type: none"> <li>• Seen by a practitioner in the past 12months</li> <li>• <b>Discussed</b> falls or problems with balance or walking with their current practitioner</li> </ul> </li> <li>2. <i>Managing</i> Fall Risk <ul style="list-style-type: none"> <li>• Had a fall or problems with balance or walking in the past 12months</li> <li>• Seen by a practitioner in the past 12months</li> </ul> </li> </ol> <p>Received a <b>recommendation</b> for how to prevent falls or treat problems with balance or walking from their current practitioner</p>
<p><b>Management of Urinary Incontinence in Older Adults</b></p> <p>Adults ages 65 and older</p>	<ol style="list-style-type: none"> <li>1. <i>Discussing</i> Urinary Incontinence <ul style="list-style-type: none"> <li>• Reported having urine leakage in the past 6 months</li> <li>• <b>Discussed their urinary leakage</b> problem with a healthcare provider</li> </ul> </li> <li>2. <i>Discussing Treatment of</i> Urinary Incontinence <ul style="list-style-type: none"> <li>• Reported having urine leakage in the past 6 months</li> <li>• <b>Discussed treatment options</b> for their current urine leakage problem</li> </ul> </li> <li>3. <i>Impact of</i> Urinary Incontinence <ul style="list-style-type: none"> <li>• Reported having urine leakage in the past 6 months</li> <li>• Reported that urine leakage made them change their daily activities or interfered with their sleep a lot.</li> </ul> </li> </ol>
<p><b>Physical Activity in Older Adults</b></p> <p>Adults ages 65 and older</p>	<p><b>Had a doctor's visit in the past 12 months</b></p> <ol style="list-style-type: none"> <li>1. <b>Discussing</b> Physical Activity: Spoke with a doctor or other health provider about their level of exercise or physical activity</li> <li>2. <b>Advising</b> Physical Activity: Received advice to start, increase or maintain their level of exercise or physical activity</li> </ol>

<sup>1</sup> HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS® MY 2022, please contact the Quality Improvement Dept. at 757-252-8400 or toll-free at 1-844-620-1015

## Measures Collected through Electronic Clinical Data Systems (ECDS)

Measure	Screen, test, care needed
<p>Childhood Immunization Status</p> <p><b>Newly Specified for ECDS Reporting</b></p> <p>Children who turn 2 years old during the measurement year</p> <p><b>Note: Vaccines must be completed on or before on or before the 2nd birthday</b></p> <p><b>Documented history of illness, a seropositive test result or anaphylaxis, there must be a note indicating the date of the event, which must have occurred by the member's second birthday.</b></p>	<ul style="list-style-type: none"> <li>• 4 DTaP, anaphylaxis, or encephalitis due to diphtheria, tetanus or pertussis vaccine (do not count any before 42 days of age)</li> <li>• 3 IPV (do not count any before 42 days of age)</li> <li>• 1 MMR or history of measles, mumps, and rubella (do not count any before 42 days of age)</li> <li>• 3 HiB or anaphylaxis to HiB vaccine (do not count any before 42 days of age)</li> <li>• 3 Hepatitis B, anaphylaxis due to hepatitis B vaccine, positive serology, or history of hepatitis B</li> <li>• 1 VZV, positive serology, or documented history of chicken pox disease</li> <li>• 4 pneumococcal conjugates (do not count any before 42 days of age)</li> <li>• 1 Hepatitis A, or documented Hepatitis A illness</li> <li>• 2 or 3 Rotavirus vaccines-depends on the vaccine administered (do not count any before 42 days of age), or documented anaphylaxis due to the rotavirus vaccine</li> <li>• 2 Influenza with different dates of service. One of the two vaccinations can be an LAIV- live attenuated influenza vaccine- if administered on the child's 2nd birthday. (do not count any given prior to 6 months of age)</li> </ul> <p><b>Exclusions: Members in hospice or using hospice services any time during the Measurement Period</b> <b>or</b> <b>Any of the following on or before the child's second birthday:</b></p> <ul style="list-style-type: none"> <li>- Severe combined immunodeficiency.</li> <li>- Immunodeficiency.</li> <li>- HIV</li> <li>- Lymphoreticular cancer, multiple myeloma, or leukemia.</li> <li>- Intussusception</li> </ul>
<p>Immunizations for Adolescents</p> <p><b>Newly Specified for ECDS Reporting</b></p> <p>Adolescents who turn 13 years old during the measurement year</p> <p>NOTE: This measure includes the Human Papillomavirus Vaccine (HPV) for both males and females.</p>	<ul style="list-style-type: none"> <li>• 1 dose Meningococcal vaccine between the 11th and 13th birthdays and</li> <li>• 1 tetanus, diphtheria toxoids and acellular pertussis (Tdap) vaccine between the 10th and 13th birthdays and</li> <li>• 2-dose or 3-dose HPV vaccination series between the 9<sup>th</sup> and 13th birthdays</li> </ul> <p><b>NOTE: All vaccines must be completed on or before the 13th birthday</b></p> <p><b>Exclusions: Members in hospice or using hospice services anytime during the measurement year</b></p>

<sup>1</sup> HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

## Measures Collected through Electronic Clinical Data Systems (ECDS)

Measure	Screen, test care needed
<p><b>Metabolic Monitoring for Children and Adolescents on Antipsychotics</b></p> <p>Newly Specified for ECDS Reporting</p> <p>Children/Adolescents ages 1-17</p>	<p>Children and adolescents 1–17 years of age who had two or more antipsychotic prescriptions and had metabolic testing during the measurement year.</p> <p>Three rates are reported:</p> <ul style="list-style-type: none"> <li>• Blood glucose or HbA1c test during the measurement year (2021)</li> <li>• LDL-C or cholesterol test during the measurement year (2021) The percentage of children and adolescents on antipsychotics who received blood glucose testing.</li> <li>• Blood glucose or HbA1c test and LDL-C or cholesterol test during the measurement year (2021).</li> </ul> <p>Exclusions:</p> <ul style="list-style-type: none"> <li>• Members in hospice or using hospice services anytime during the measurement year.</li> <li>• Members with a diagnosis of narcolepsy any time during the member’s history through the end of the Measurement Period (January 1 through December 31, 2021).</li> </ul>
<p><b>Adult Immunization Status</b></p> <p>Adults 19 years of age and older</p> <p>CPT Codes: Influenza: 90655; 90657; 90661; 90673; 90685- 90689 Td or Tdap: 90714-91705; 90718 Zoster: 90736 Pneumococcal: 90732</p>	<p>Received recommended routine vaccines:</p> <ul style="list-style-type: none"> <li>• Influenza vaccine on or between July 1, 2020 - June 30, 2021</li> <li>• Td or Tdap on or between January 1, 2012-December 31, 2021</li> <li>• Zoster (one dose of herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine, at least 28 days apart anytime on or after the member’s 50th birthday</li> <li>• Pneumococcal vaccine on or after the member’s 60th birthday</li> </ul> <p>Exclusions:</p> <ul style="list-style-type: none"> <li>• Members in hospice or using hospice services anytime during the measurement year.</li> <li>• Members with bone marrow transplant or on active chemotherapy during the measurement year (2021)</li> <li>• Members with a history of immunocompromising conditions, cochlear implants, anatomic or functional asplenia, sickle cell anemia and HB-S disease, or cerebrospinal fluid leaks anytime during the members history through the end of the measurement year (2021).</li> </ul>

<sup>1</sup> HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

## Measures Collected through Electronic Clinical Data Systems (ECDS)

Measure	Screen, test, or care needed
<p><b>Prenatal Immunization Status</b></p> <p>Deliveries in the measurement year (2021)</p>	<p><b>Received recommended vaccines:</b></p> <ul style="list-style-type: none"> <li>• Influenza (between July 1, 2020 and delivery date in 2021)</li> <li>• Tetanus, diphtheria toxoids and acellular pertussis (Tdap) during the pregnancy (including on the delivery date)</li> </ul> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>• Deliveries in which members were in hospice or using hospice services any time during the Measurement Period.</li> <li>• Deliveries that occurred at less than 37 weeks gestation.</li> </ul>
<p><b>Prenatal Depression Screening and Follow-up</b></p>	<p>Screened for clinical depression while pregnant. If screening is positive, received follow-up care.</p> <p>Two rates are reported:</p> <ul style="list-style-type: none"> <li>• Depression Screening: Screened for clinical depression during pregnancy using a standardized instrument.</li> <li>• Follow up on Positive Screen: Received follow-up care within 30 days of a positive depression screening finding.</li> </ul> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>• Deliveries in which members were in hospice or using hospice services any time during the Measurement Period.</li> <li>• Deliveries that occurred at less than 37 weeks gestation.</li> </ul>
<p><b>Post-Partum Depression Screening and Follow-up</b></p>	<p>Screened for clinical depression postpartum. If screening is positive, received follow-up care.</p> <p>Two rates are reported:</p> <ul style="list-style-type: none"> <li>• <i>Depression Screening</i>: Screened for clinical depression using a standardized instrument during the postpartum period (7-84 days following date of delivery).</li> <li>• <i>Follow-up on Positive Screen</i>: Received follow-up care within 30 days of a positive depression screen finding.</li> </ul> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>• Deliveries in which members were in hospice or using hospice services any time during the Measurement Period.</li> </ul>

<sup>1</sup> HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

## Measures Collected through Electronic Clinical Data Systems (ECDS)

Measure	Screen, test, care needed
<p><b>Depression Screening and Follow-Up for Adolescents and Adults</b></p> <p>Ages 12 years and older</p>	<ul style="list-style-type: none"> <li>Screened for depression using a standardized tool</li> <li>If screening was positive, received <b>follow-up care within 30 days</b> (e.g., an outpatient or telephone follow-up visit; a depression case management encounter; a behavioral health encounter; dispensed antidepressant medication)</li> </ul> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>Members in hospice or using hospice services anytime during the measurement year.</li> <li>Members with bipolar disorder in the prior measurement year (2020).</li> <li>Members with depression that starts in the prior year (2020) through the measurement year (2021).</li> </ul>
<p><b>Unhealthy Alcohol Use Screening and Follow-Up Adults ages 18 and older</b></p>	<ul style="list-style-type: none"> <li>Screened for unhealthy alcohol use using a standardized tool (AUDIT, Single-Question Screen)</li> <li>If screening was positive, received brief counseling or other follow-up care within 2 months (e.g., feedback on alcohol use and harms; identification of high-risk situations for drinking and coping strategies; development of a personal plan to reduce drinking; documentation of receiving alcohol misuse treatment).</li> </ul> <p><b>Exclusions: Members in hospice or using hospice services anytime during the measurement year</b></p>
<p><b>Depression Remission or Response for Adolescents and Adults</b></p> <p>Ages 12 and older</p> <p>ICD-10 Codes to identify Major Depression and Dysthymia: F32.0-F32.5; F32.9; F33.0-F33.3; F43.40-F43.42; F33.9; F34.1</p> <p>CPT Codes to identify Interactive Outpatient Encounters: 90791; 90792; 90832; 90834; 90837; 98960-98962; 99078; 99201-99205; 99211- 9215;99217-99220; 99241-99245; 99341-99345;99347-99350; 99381-99387; 99391-99397;99401-99404; 99411-99412; 99483; 99510</p>	<ul style="list-style-type: none"> <li>Diagnosis of major depression or dysthymia</li> <li>An elevated PHQ-9 (total score &gt;9)</li> <li>Evidence of response or remission within 4-8 months of the elevated score</li> </ul> <p>Four rates are reported:</p> <ol style="list-style-type: none"> <li>ECDS Coverage: Health plan can receive any electronic clinical quality data</li> <li>Follow-Up PHQ-9 within 4-8 months of the elevated score</li> <li>Depression Remission: PHQ-9 score of &lt;5</li> <li>Depression Response: a PHQ-9 score reduction of at least 50%</li> </ol> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>Bipolar disorder; Personality disorder; Psychotic disorder, Pervasive Developmental disorder</li> <li>Members in hospice or using hospice services anytime during the measurement year.</li> </ul>

<sup>1</sup> HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS® MY 2022, please contact the Quality Improvement Dept. at 757-252-8400 or toll-free at 1-844-620-1015

## Measures Collected through Electronic Clinical Data Systems (ECDS)

Measure	Screen, test, or care needed
<p><b>Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults</b></p> <p><b>Ages 12 and older</b></p> <p><b>ICD-10 Codes to identify Major Depression and Dysthymia:</b></p> <p>F32.0-F32.5; F32.9; F33.0-F33.3; F43.40-F43.42; F33.9; F34.1</p> <p><b>CPT Codes to identify Interactive Outpatient Encounters:</b></p> <p>90791; 90792; 90832; 90834; 90837; 98960-98962; 99078; 99201-99205; 99211-99215; 99217-99220; 99241-99245; 99341-99345; 99347-99350; 99381-99387; 99391-99397; 99401-99404; 99411-99412; 99483; 99510</p> <p><b>LOINC Codes to identify PHQ administered:</b></p> <p>44261-6; 89204-2</p>	<ul style="list-style-type: none"> <li>• Diagnosis of major depression or dysthymia</li> <li>• Had a PHQ-9 or PHQ-A tool administered during an outpatient encounter at least once during a four-month period</li> </ul> <p>Two rates are reported:</p> <ol style="list-style-type: none"> <li><b>1. Inclusion in ECDS Rate:</b> The percentage of members 12 and older with a diagnosis of major depression or dysthymia, who are included in an electronic clinical data system (ECDS).</li> <li><b>2. Utilization of PHQ-9 Rate:</b> The percentage of PHQ utilization. Members with a diagnosis of major depression or dysthymia who are covered by an ECDS and, if they had an outpatient encounter, have a PHQ-9 score present in their record.</li> </ol> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>• <b>Bipolar disorder; Personality disorder; Psychotic disorder, Pervasive Developmental disorder</b></li> <li>• <b>Members in hospice or using hospice services anytime during the measurement year.</b></li> </ul>

<sup>1</sup> HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

For more information regarding HEDIS® MY 2022, please contact the Quality Improvement Dept. at 757-252-8400 or toll-free at 1-844-620-1015